Use of moderate hypofractionated radiotherapy in craniopharyngioma
Advances in Radiotherapy & Nuclear Medicine · 2024
DOI: 10.36922/arnm.3041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, 2024. Verfasst von Can Azak und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
External beam radiation therapy is used for inoperable, residual, or recurrent disease after surgery for craniopharyngioma. At present, conventional radiotherapy, hypofractionated radiotherapy (HFRT), and stereotactic radiotherapy (SRT) are available options. However, there are limited data on HFRT and SRT using modern radiotherapy (RT) devices. This paper presents the findings of a retrospective study conducted at a single institution based on our long-term experiences with eight craniopharyngioma patients who had underwent RT. The median time between the operation and RT was 8.5 months (ranging from 2.6 to 11 months). Six patients were treated with CyberKnife® (CK®), and two were treated with Tomotherapy® (HT®) using the helical intensity-modulated RT technique (H-IMRT). Patients treated with HT received a mean of 50 and 55 Gy RT in 25 and 30 fractions (conventional RT scheme), respectively. Out of the six patients treated with CK, three received a mean of 22 – 25 Gy in five fractions, and the other three received a mean of 40 – 42 Gy in 15 fractions. The median follow-up was 6 years (range: 2 – 9.1 years), and no progression was observed. The 3-year overall survival (OS) and progression-free survival (PFS) rates were 85.7% and 85.7%, respectively. OS and PFS at 5 years were likewise 85.7% and 85.7%, respectively. Of the two patients (25%) who were alive with a complete response, one received 50 Gy in 25 fractions with H-IMRT, and the other received RT through CyberKnife with five fractions. Five patients (62.5%) were alive with stable residual disease and one patient had died with a complete response. HFRT may be considered as a preferable option in the treatment of craniopharyngioma, in addition to conventional or SBRT treatment options.
Zitieren
APA
Azak, C., Çamlıcalı, H., Karakaya, E., Öztürk, K., Akkaş, E. A., Alioğlu, F., Altundağ, M. B., & Güney, Y. (2024). Use of moderate hypofractionated radiotherapy in craniopharyngioma. Advances in Radiotherapy & Nuclear Medicine. https://doi.org/10.36922/arnm.3041
Vancouver
Azak C, Çamlıcalı H, Karakaya E, Öztürk K, Akkaş EA, Alioğlu F, et al. Use of moderate hypofractionated radiotherapy in craniopharyngioma. Advances in Radiotherapy & Nuclear Medicine. 2024. doi:10.36922/arnm.3041
BibTeX
@article{Azak2024,
author = {Azak, Can and Çamlıcalı, Hasan and Karakaya, Ebru and Öztürk, Koray and Akkaş, Ebru Atasever and Alioğlu, Fatma and Altundağ, Muzaffer Bedri and Güney, Yıldız},
title = {Use of moderate hypofractionated radiotherapy in craniopharyngioma},
journal = {Advances in Radiotherapy & Nuclear Medicine},
year = {2024},
doi = {10.36922/arnm.3041}
}
EUVIMED